[go: up one dir, main page]

AR071100A1 - Composicion farmaceutica 271, para el tratamiento del cancer - Google Patents

Composicion farmaceutica 271, para el tratamiento del cancer

Info

Publication number
AR071100A1
AR071100A1 ARP090101107A ARP090101107A AR071100A1 AR 071100 A1 AR071100 A1 AR 071100A1 AR P090101107 A ARP090101107 A AR P090101107A AR P090101107 A ARP090101107 A AR P090101107A AR 071100 A1 AR071100 A1 AR 071100A1
Authority
AR
Argentina
Prior art keywords
benzoimidazol
phenylamino
bromo
fluoro
ethoxy
Prior art date
Application number
ARP090101107A
Other languages
English (en)
Inventor
Kathryn Jane Hill
Nicola Frances Batman
Paul Richard Gellert
Original Assignee
Astrazeneca Ab
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Array Biopharma Inc filed Critical Astrazeneca Ab
Publication of AR071100A1 publication Critical patent/AR071100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Concierne a composiciones farmacéuticas que contienen una sal de sulfato de hidrogeno de -6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-ácido carboxílico (2-hidroxi-etoxi)-amida y solvatos, formas cristalinas y formas amorfas de las mismas, para el uso de dichas composiciones como un medicamento; y a los procesos para la preparacion de dichas composiciones. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5- ácido carboxílico (2-hidroxi-etoxi)-amida, y una matriz portadora, donde la matriz portadora consiste esencialmente en uno o más portadores farmacéuticamente aceptables seleccionados de los siguientes grupos: (a) succinato de d-alfa-tocoferil polietileno glicol 1000; (b) glicéridos poliglicolizados; (c) polietileno glicoles (PEG); y (d) grasas duras; y donde la sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-ácido carboxílico (2-hidroxi-etoxi)-amida es dispersada dentro de la matriz portadora. Reivindicacion 12: Una composicion farmacéutica de acuerdo a la reivindicacion 1, caracterizada porque comprende: (i) de 15 a 25 partes de una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-ácido carboxílico (2-hidroxi-etoxi)-amida; y (ii) de 75 a 85 partes de Vitamina E TPGS; donde ambas partes son por peso y la suma de las partes (i) + (ii) = 100; y donde la sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-ácido carboxílico (2-hidroxi-etoxi)-amida es dispersada dentro de la Vitamina E TPGS y la composicion es semisolida o solida a temperatura ambiente. Reivindicacion 20: Una composicion farmacéutica de acuerdo a cualquiera de las reivindicaciones 1 a 15 caracterizada porque se usa como un medicamento en el tratamiento de cáncer.
ARP090101107A 2008-03-28 2009-03-27 Composicion farmaceutica 271, para el tratamiento del cancer AR071100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4037208P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
AR071100A1 true AR071100A1 (es) 2010-05-26

Family

ID=40792932

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090101107A AR071100A1 (es) 2008-03-28 2009-03-27 Composicion farmaceutica 271, para el tratamiento del cancer
ARP190102398A AR116001A2 (es) 2008-03-28 2019-08-23 Composición farmacéutica 271

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190102398A AR116001A2 (es) 2008-03-28 2019-08-23 Composición farmacéutica 271

Country Status (30)

Country Link
US (12) US20090246274A1 (es)
EP (1) EP2271321B1 (es)
JP (2) JP5547710B2 (es)
KR (1) KR101650958B1 (es)
CN (1) CN102046156B (es)
AR (2) AR071100A1 (es)
AU (1) AU2009229204B2 (es)
BR (1) BRPI0909267B8 (es)
CA (1) CA2718653C (es)
CL (1) CL2009000765A1 (es)
CO (1) CO6311068A2 (es)
CY (1) CY1113279T1 (es)
DK (1) DK2271321T3 (es)
EC (1) ECSP10010578A (es)
ES (1) ES2387942T3 (es)
HR (1) HRP20120657T1 (es)
IL (1) IL208206A0 (es)
MX (1) MX2010010671A (es)
MY (1) MY157492A (es)
NZ (1) NZ588849A (es)
PE (1) PE20091755A1 (es)
PL (1) PL2271321T3 (es)
PT (1) PT2271321E (es)
RS (1) RS52409B (es)
SA (1) SA109300195B1 (es)
TW (1) TWI433840B (es)
UA (1) UA101654C2 (es)
UY (1) UY31737A (es)
WO (1) WO2009118562A1 (es)
ZA (1) ZA201006766B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
KR102160320B1 (ko) 2012-10-02 2020-09-28 에피테라퓨틱스 에이피에스 히스톤 탈메틸효소의 저해제
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
TW201625535A (en) 2014-03-31 2016-07-16 Epitherapeutics Aps Inhibitors of histone demethylases
TW201625536A (zh) 2014-08-27 2016-07-16 艾比療法公司 抑制組蛋白去甲基酶之化合物及方法
CN121443286A (zh) * 2023-05-25 2026-01-30 地图之光治疗股份有限公司 用于治疗神经障碍的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
ES2170143T3 (es) 1994-04-07 2002-08-01 Smithkline Beecham Plc Composiciones que comprenden halofantrina en una forma especial.
EP0825849A1 (en) 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
NZ336900A (en) 1997-01-30 2001-06-29 Novartis Ag Hard gelatine capsules containing pharmaceutical compositions comprising cyclosporin A and being substantially free of any oil
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
WO2004026235A2 (en) 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
KR20080093464A (ko) * 2003-09-02 2008-10-21 화이자 프로덕츠 인크. 지프라시돈 나노입자
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
CA2552925A1 (en) 2004-01-30 2005-08-18 Pfizer Italia S.R.L. Semisolid matrix pharmaceutical formulations
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20070060610A1 (en) 2005-06-16 2007-03-15 Wempe Michael F Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US8765661B2 (en) 2008-03-20 2014-07-01 Virun, Inc. Compositions containing non-polar compounds
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
BRPI0909267A2 (pt) 2017-05-30
JP2011515455A (ja) 2011-05-19
JP2014114320A (ja) 2014-06-26
US20200179344A1 (en) 2020-06-11
US20170056375A1 (en) 2017-03-02
HK1156844A1 (zh) 2012-06-22
UA101654C2 (uk) 2013-04-25
CO6311068A2 (es) 2011-08-22
BRPI0909267B8 (pt) 2021-05-25
CN102046156B (zh) 2014-12-17
US20120114750A1 (en) 2012-05-10
WO2009118562A1 (en) 2009-10-01
US12318367B2 (en) 2025-06-03
CL2009000765A1 (es) 2011-02-11
BRPI0909267B1 (pt) 2020-07-07
US20240423960A1 (en) 2024-12-26
US20190030004A1 (en) 2019-01-31
CA2718653C (en) 2016-02-09
MY157492A (en) 2016-06-15
AU2009229204A1 (en) 2009-10-01
CN102046156A (zh) 2011-05-04
US20240041834A1 (en) 2024-02-08
RS52409B (sr) 2013-02-28
US20130195971A1 (en) 2013-08-01
US20220087982A1 (en) 2022-03-24
CY1113279T1 (el) 2016-04-13
TW200946511A (en) 2009-11-16
ECSP10010578A (es) 2010-11-30
KR20110005246A (ko) 2011-01-17
US12364684B2 (en) 2025-07-22
US20160030574A1 (en) 2016-02-04
IL208206A0 (en) 2010-12-30
US20250000848A1 (en) 2025-01-02
JP5547710B2 (ja) 2014-07-16
EP2271321B1 (en) 2012-06-13
CA2718653A1 (en) 2009-10-01
ZA201006766B (en) 2011-05-25
EP2271321A1 (en) 2011-01-12
AR116001A2 (es) 2021-03-25
RU2491920C2 (ru) 2013-09-10
TWI433840B (zh) 2014-04-11
HRP20120657T1 (hr) 2012-09-30
HK1149476A1 (en) 2011-10-07
UY31737A (es) 2009-11-10
ES2387942T3 (es) 2012-10-04
US11813246B2 (en) 2023-11-14
DK2271321T3 (da) 2012-08-27
US12465593B2 (en) 2025-11-11
KR101650958B1 (ko) 2016-08-24
US12220403B2 (en) 2025-02-11
US20240041835A1 (en) 2024-02-08
US20090246274A1 (en) 2009-10-01
PT2271321E (pt) 2012-08-16
SA109300195B1 (ar) 2013-04-20
NZ588849A (en) 2012-06-29
AU2009229204B2 (en) 2012-05-24
PE20091755A1 (es) 2009-12-13
RU2010143906A (ru) 2012-05-10
PL2271321T3 (pl) 2013-03-29
MX2010010671A (es) 2011-06-20

Similar Documents

Publication Publication Date Title
AR071100A1 (es) Composicion farmaceutica 271, para el tratamiento del cancer
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20220387A1 (es) Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer
CU20110212A7 (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CR20140113A (es) Imidazopiridazinas sustituidas con amino
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
SV2016005229A (es) Inhibidores de syk
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
DOP2014000055A (es) Derivados de pirrolopirimidina y purina
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30094A1 (es) Compuestos químicos
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CO6430500A2 (es) Composición de liposoma
CR20160064A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
UY30282A1 (es) Compuestos quimicos
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
ECSP11011257A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
UY31141A1 (es) Compuestos de piperidina y sus usos
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo

Legal Events

Date Code Title Description
FC Refusal